The Seven Investments
You Have to Make in 2013

Our special report "The Five Stocks You Have to Own in 2012" proved to be a big winner – with readers and with investors. Two of the stocks doubled in price, and the biggest winner posted a peak gain of 153%.

Readers asked that we offer this special report again in the New Year. And we're glad to do so.

In this year's report, we offer:

And that's just four of the offerings that appear in today's report, "The Investments You Have to Make in 2013."

The report is free as part of your subscription. Consider it a formal "thank you" for your loyal support in 2012. And please know that we'll offer regular updates – just as we did with the recommendations in last year's report.

Now that we've made our introduction, let's move right into this year's recommendations.

Keith Fitz-Gerald, Chief Investment Strategist
and Editor of The Geiger Index and Strike Force

Keith wears multiple hats here at Money Map Press – and wears them well. In addition to the multiple advisory services he runs, he also serves as chief investment strategist for the entire group.

Not surprisingly, Keith picked the stock that recorded the largest peak gain for our "Five Stocks You Have to Own in 2012" report. His pick, NQ Mobile Inc. (NYSE ADR: NQ) went from $5.02 to as high as $12.70, for a peak gain of 153%. The stock subsequently sold off and then dropped on "guilt-by-association" concerns that China's military might be using China-based companies to spy on U.S. companies (which is why we urge investors to use "trailing stops," or Keith's "free-trade" strategy on stocks that double).

NQ subsequently rebounded and is up 33% – with strong long-term prospects.

Keith is staying in the security arena with his 2013 recommendation.

"For our pick for the rest of this year, I'm thinking we can go with CommTouch Software Ltd.(NasdaqCM: CTCH)," Keith said. "It's trading at just under $3 a share, and has a market cap of only $72 million – so there's planet of room to grow or be acquired.We originally recommended it in Strike Force back in July, and continue to like its prospects."

Founded in 1991, CommTouch is based in Netanya, Israel, and provides proven Internet security technology to more than 150 security companies and service providers. The company offers white-label and cloud-based Internet security solutions to companies that, in turn, offer privately branded Internet security offerings to their end users.

CommTouch's client list already includes a "Who's Who" in the tech world, with clients like 1&1, Check Point, F-Secure, Google, Microsoft, McAfee, Net Gear, Panda Security, Rackspace, U.S. Internet, WatchGuard, and Webroot, just to name a few.

CommTouch's antivirus engine recently placed first out of 31 products tested with a detection rate of 99.98% in the May 2012 AV Test performed by AV-Test GmbH, a respected service provider for IT security testing with more than 15 years of experience in the area of antivirus research and data security.

"From 2006 to 2011, the company experienced average annual revenue growth of 36.5%, advancing from $7.23 million in 2006 to $23.02 million in 2011. As of Sept. 30, 2012, the company reported $17.33 million in cash and no long-term debt," Keith continued. "The company's market cap is only $73.3 million, which means the $17.33 million in cash covers more than 23.64% of its current market cap. I like that because it means that for every $3.01 in share value, investors are effectively paying $2.30 for the company's operations, and getting 71 cents a share in cash. With no debt, a solid user base, and proven technology, it's only a matter of time before somebody wants an exclusive – that's why I expect CommTouch to be bought out."

In mid-November, CommTouch announced it had acquired the Berlin, Germany-based eleven GmbH. eleven is a provider of mail-based Security-as-a-Service (SecaaS) solutions, capturing more than 36% of the German market for managed e-mail security.

Because of the buyout, CommTouch increased its revenue guidance and said fiscal 2012 revenue would be in the range of $23.7 million to $23.9 million. The acquisition would be accretive, with a modest positive contribution for the fourth quarter of 2012; accordingly, the company reiterated its expectation that fiscal 2012 non-GAAP net income would be greater than $4.0 million.

According to I/B/E/S Estimates, analysts on average were expecting the company to report revenue of $23.0 million and net income of $3.4 million for fiscal 2012.

Analysts have a consensus target price of $3.50 a share on the stock, which would represent a return of 55% from current levels.

Recommendation: Buy CommTouch Software Ltd.(NasdaqCM: CTCH), recent price $2.95. Employ a "trailing stop" of 30%.

Peter Krauth, Editor Real Asset Returns

Peter had one of the top picks last year in Sandstorm Gold Ltd. (TSE: SSL), which soared as much as 142% – and which is still up 90% as we write this.

His pick this year is another small producer – this time Aurcana Corp. (TSXV: AUN), a junior silver miner. Aurcana is currently producing in Mexico, and in December started commercial production at a second mine in Texas.

The La Negra Mine, 180 kilometers north of Mexico City, produces silver, copper, zinc and lead.  This year, it's expected to produce 1.33 million ounces of silver.  But thanks to byproduct credits from the three other base metals, expected cash costs as of the fourth quarter of 2012 were negative 21 cents per silver equivalent ounce. 

"Last April, Aurcana completed a mill expansion to 2,500 tons per day (TPD), and there are plans to expand to 3,000 tons per day.  What's more, there's also the potential to increase the average mill head grade to 100g/t up from the current 80 g/t … technical-speak that tells us that each ton of silver going into the mill has a higher silver content, so each ton milled produces more silver," Peter said. "But the really big news at La Negra is the recent resource statement that this project holds a whopping 115 million measured and indicated silver ounces.  Even with that, there is still significant expansion potential, with the deposit open at depth and along strike, as the company plows forward with a 14,000 meter annual drilling program."

A key point, says Peter: "The historic resource was only 4.9 million ounces, so this revision is somewhat of a game changer, and I think it could make Aurcana a takeover target."

If that was all that Aurcana had going for it, the stock would probably be a "Buy" all by itself.

But there's more.

Shafter is Aurcana's Texas Project, which is a pure silver mine about 375 kilometers southeast of El Paso.  Mining started last April, with commercial production expected by the fourth quarter – at a rate of 3.8 million ounces of silver for a cash cost of  approximately $10 per ounce. 

The current resource at Shafter is 24 million ounces in the measured and indicated categories, plus an additional 23 million ounces in the inferred category.

With Shafter, management's objective is clear: Expand Shafter's mill capacity from 1,500 tons per day to 2,500 tons per day, for a very reasonable $3 million capital outlay. That would pop production from 3.8 million silver ounces to 6.3 million silver ounces annually (a 65% increase, just at Shafter) – making it the largest pure silver mine in the U.S. market.

Here, too, exploration is ongoing: There's a $3 million budget for 2012, as the resource remains open both at depth and along strike.

"The major impetus for Aurcana's shares to gain is the likely 're-rating' by the market, as the company eventually shows significantly higher overall production numbers boosted by Shafter," Peter explained. "That will push production up by nearly 300%. There are currently 1.3 million ounces of output from La Negra, but the upcoming 3.8 million ounces from Shafter should push next year's total output to 5.1 million ounces.  What's more, both mines could see further production and resource growth in relatively short order."

The outlook for the stock, according to Peter: "Currently trading at 88 cents a share, I could easily see 50% gains within six months, and a double within 12 months for Aurcana."

Recommendation:  Buy Aurcana Corp. (TSXV: AUN) at the market, and use a 50% trailing stop.

Michael A. Robinson, Editor Radical Technology Profits

Most of you folks know Michael Robinson as our resident tech guru – and probably also as a guy who's made some highly profitable (and remarkably timely) calls both here in Private Briefing and in his own service, Radical Technology Profits.

But his expertise isn't limited to technology.

You see, to succeed in the high-tech realm, an investor like Michael has to be able to sniff out the tiny, emerging ventures that have the greatest chance of turning into big winners. That's a real gift.

Most investors have no idea just how many small companies there really are to sort through. And, as I know from my many years as a business journalist, the vast majority of these little players are one-trick ponies, flame-out candidates, empty shells, also-rans or outright frauds.

Out of the thousands of smallish firms that occupy each business sector, there are literally just a few that have any kind of chance of lasting success. And in that small group there's perhaps one or two that can make an investor some real money – but only if you can identify the company and buy the stock before it makes its move … and before it becomes "common knowledge" among Wall Streeters and retail-investing America.

The bottom line for a guy like Michael is this: To be a successful tech guru, you also have to be an expert in small-cap stocks.

His recommendation is actually a small-cap rarity. It's one of those stocks that you find once in a very great while … one that has a payoff potential in both the short-term – and over the long haul.

The company in question is the San Diego-based AMN Healthcare Services Inc. (NYSE: AHS). It's a provider of healthcare-recruitment and staffing services to hospitals, pharmacies, and public-and-private healthcare centers.

"Investors might find it curious that I characterize this as an emerging small-cap," Michael said. "After all, the firm has been around since the 1980s, when it focused on the travel-nurse industry. But the fact is that this company has drastically changed its business model since that time, and has a market cap that's just over $500 million."

AMN Healthcare seems to have positioned itself for the ideal business opportunities at the perfect time.

"With the election now behind us, investors can count on the broad changes that Obamacare will usher in," Michael explained. "Because AMN ranks as the industry's largest healthcare-staffing and permanent-placement firm, it will benefit greatly from the push that service providers are making to hire in order to deal with the looming changes. In fact, I see this as a growth business as the underlying Obamacare law takes effect in stages through 2014."

As we said, though, the profit opportunities here are both near-term and long-term in nature. That's because U.S. demographics will work in the company's favor, as well.

The number of Americans over the age of 65 rose from about 35 million in 2000 to more than 40 million today. The last time I checked, the number of Americans aged 85 and older was projected to zoom from about 2% of the nation's population in 2010 to roughly 5% in 2050. Healthcare already accounts for about 18% of U.S. gross domestic product (GDP) and one forecast I just read is projecting it to reach 40% by 2050.

You can bet this means that the demand for nurses and doctors will continue to soar. I can speak from personal experience on this point. My own mother was a nurse her entire career; thanks to the perennial shortage of licensed nurses, she was able to work into her early 70s, and could have continued as a full- or part-timer had she wished. (If you'll excuse a bit of bias here, her warm-and-compassionate demeanor helped keep her in demand, too – the patients and her co-workers always asked to work with her.)

Healthcare analysts are projecting a shortage of doctors (130,000) and registered nurses (260,000) that they say will pretty much remain permanent for the foreseeable future.

"The bottom line here is that AMN can count on a strong, long-term demand for its services," Michael said. "Aging Baby Boomers and a generally longer life expectancy will increase the patient load – even as there's a shortage of young clinicians to take care of them. If that wasn't enough, this big-and-growing demand/supply imbalance comes along at a time when medical firms will face increased cost pressures, meaning many will opt to hire on a contract basis, allowing them to keep a lid on employee overhead by skimping on benefits."

Michael's somewhat concerned about profit margins, since that's a measure of how much a company keeps from the sales it generates. The higher the margin percentage, the more money the company has available to invest in future growth.

But its current margins are slightly higher than what the company has been averaging – a positive trend, if it continues.

The earnings trend also appears to be highly positive.

The stock has been on a roll, having doubled from its early-August trough. But the stock is still cheap – in fact, very cheap – with a powerful chart.

"I'd like to see higher margins but there's no denying the demand for this low-priced stock." Michael said. "With a market cap of about $550 million, it trades at around $12.30 a share with a Price/Sales (P/S) ratio of 0.50 and a "PEG' ratio just under 2.0. The technicals also look good."

Recommendation: AMN Healthcare Services Inc. (NYSE: AHS), recent price $12.30.

Dr. Kent Moors, Editor of the Energy Advantage
and Energy Inner Circle

Oil refiners have been on a scorching run.

If you acted on our Oct. 31, 2011 recommendations ("Strike Black Gold With These Two Stocks") of refiners HollyFrontier Corp. (NYSE: HFC) and Valero Energy Corp. (NYSE: VLO), you've done exceptionally well.

As of Jan. 31, HollyFrontier shares are up 70%. And Valero has done even better: Its shares have soared more than 78%.

But that surge, which has accelerated since the start of the year, isn't likely to be followed by a drop-off.

And Kent – our resident energy expert and the editor of several energy-related advisory services here at Money Map Press – believes there's even more to come for refiners.

"Refinery stocks have done very well for our subscribers … and they remain very good picks," Kent told me.  "We are now seeing clear signs of a breakout in the oil sector, but it's important to keep in mind that the market will remain choppy for some time."

When I asked him to list his favorite refinery stocks, Kent specifically cited HollyFrontier and Valero as part of this "short list." Valero, in particular, is among the best-positioned for an upward market and still has plenty of upside.

"A refiner like VLO will continue to appreciate, albeit at slower increments than over the past month," Kent told me. "But that's perfectly fine: It makes this stock a very good candidate for a long-term hold," meaning it's a stock you can expect to hold onto and profit from for an extended stretch.

In late January, Valero reported what analysts unanimously described as a "blowout" fourth quarter, with profits soaring from eight cents to $1.82 per share – trouncing the consensus estimate, despite flat revenue.

What was the catalyst for this big fourth-quarter jump in profits?

Valero CEO Bill Klesse said the company "replaced all imported light foreign crude oils with cheaper domestic crude oils at our Gulf Coast and Memphis refineries. Since we expect U.S. and Canadian crude oils to become increasingly more available, we are pursuing options to process additional volumes of these cost-advantaged crudes throughout our refining system."

Traditionally, U.S. refiners have used crude oil from foreign suppliers as the "raw material" for their operations. But now they can shift to much cheaper crude that's sourced from domestic shale. That's given U.S. domestic refiners a cost advantage they didn't have before. And since oil-shale is just coming into its own as a permanent source of crude, this cost advantage may hold.

So what's Kent's advice? Well, he believes these stocks still have plenty of upside. So if you don't own any refiners, he views these stocks as solid profit opportunities, and says these are solid buys.

But risk-management remains crucial.

With new positions, be sure to employ "trailing stops." Kent recommends 30% with these stocks under current market conditions.

Recommendation: Buy Valero Energy Corp. (NYSE: VLO), recent price $43.73. Use a 30% "trailing stop."

William Patalon III, Executive Editor Money Morning
and Private Briefing

As we've told you many times, there's nothing better to find than a beaten-down stock that's experiencing massed insider buying. Insiders sell for many reasons … but they almost always buy for only one – because they see an upsurge ahead. And those folks don't go to all the trouble of buying big blocks – with all the disclosure requirements, tax issues and financing challenges involved – just to make a point or two on the stock. When insiders buy, they typically do so because they see big gains to come.

That was a basic premise of the 1998 Prentice Hall Press book "Contrarian Investing: How to Buy and Sell When Others Won't and Make Money Doing It," which I co-authored with noted New York State money manager Anthony M. Gallea.

And I've found it to be true time and time again through the years.

This "buying with the smart money" rule is the basis of my recommendation for the New Year.

In the April special report "The Biotech Buyout Binge" we recommended three oncology stocks. All three posted hefty gains, and the biggest winner was blood-cancer specialist Pharmacyclics Inc. (Nasdaq: PCYC), with a peak gain of 153%.

One of the other stocks, Vical Inc. (Nasdaq: VICL), soared as much as 40% following our recommendation. However, it subsequently sold off, and now the shares are essentially back where they started.

But we believe that a rebound is in the offing. A big one.

And the "smart money" seems to agree.

You see, since the start of this year Vical insiders - including CEO Vijay B. Samant - have snapped up 133,750 shares. The purchases were made soon after Vical announced that its Nasdaq listing had been upgraded to the Nasdaq Global Select Market. That's the highest listing of the three available and means the company is mature enough to adhere to a tougher set of financial requirements.

In addition to the insiders, James R. Singer – already a 10% beneficial owner – has added to his stake by spending $1.7 million to purchase an additional 464,300 shares at prices ranging from $3.51 to $3.99.

Those purchases were made in July, August and September, but weren't disclosed until Jan. 15, according to the Securities and Exchange Commission filing that we linked to above.

Insider selling is often inconclusive. But on a stock that's been beaten down from its highs, there's nothing that gets me more excited than insider buying. And Vical seems to have a hefty upside. The stock is currently trading at about $3.50. The consensus target is $6 a share, though the target prices go as high as $7. Those predictions would represent gains of 71% to 100% above where the stock was trading as I wrote this.

The San Diego-based Vical already has two products for sale – both for animals.

Here in the U.S. market it has approval for a vaccine that combats skin cancer in dogs. And just over the border in Canada, it has been approved to sell a vaccine that fights a virus in salmon (an especially virulent virus, I might add). Salmon, as you know, is a critical food source in that country, so this could be a relatively important product.

For humans, Vical says it will soon complete a Phase III clinical trial of Allovectin, a therapy designed to treat late-stage skin cancer that's spread to other parts of the body. And tech-guru Michael Robinson tells me the company is also in the early stages of a clinical trial for a flu vaccine.

The odds of a windfall profit from a biotech buyout are about as good as you're ever going to find. As we told you in our Jan. 9 Private Briefing report, we're expecting biotech and pharmaceutical dealmaking to soar this year - even more than it did in 2012.

And we're suddenly seeing quite a few research reports that make the same case.
There have been 676 takeovers of biotechnology and pharmaceutical companies in the past three years, and the average buyout premium has been 38%, Bloomberg News reports.

But that impact could be even bigger this year.

The five largest Big-Pharma players - including Bristol-Myers Squibb Co. (NYSE: BMY), Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) - were holding more than $70 billion in cash and cash equivalents at the close of the third quarter. Having spent the last couple of years streamlining operations and incorporating earlier buyouts, you're going to see these behemoths embark on unprecedented shopping sprees - and can expect to see deals as big as $20 billion.

"With sales declining for the first time in 2012, it is only a matter of time before shareholder returns follow suit - unless [Big Pharma] can find new sources of growth," accounting-and-consulting firm Ernst & Young said in a report released at the start of the New Year. "With few options for organic growth, Pharma needs transactions ... [and] the pool of potential suitors that could pay up to $20 billion has swelled."

It's the so-called "patent cliff" that's sparking the biggest fears. Right now, some of the biggest drugmakers have some of their most-lucrative blockbuster drugs coming "off patent" - meaning these companies face the loss of $170 billion in aggregate annual sales.

So whether it's via a buyout in the near-term or through drug development over the long haul, we believe that Vical is a stock that will make you money.

The company's insiders apparently feel the same way.

Recommendation: Buy Vical Inc. (Nasdaq: VICL), recent price 3.50. Observe position-sizing limits and use a 37% "trailing stop."

Martin Hutchinson, Editor of the Permanent Wealth Investor

A former global merchant banker who helped guide the economic restructurings of Bulgaria, Croatia and Macedonia, Martin has a reputation for gutsy predictions and impeccable timing.

He also has the honor of picking the biggest winner since we started publishing Private Briefing back in August 2011 – the peak gain of 205% in Belgium biotech Galapagos NV (PINK ADR: GLPYY).

The bottom line: Martin has the "right stuff" to make big "macro" calls … like telling us which markets are about to surge … and can then drop down and make the all-important "micro" calls … like recommending the "right" stocks to buy in those surging economies.

And while 2012 was the year of the "developed" economy stock, the New Year will be all about the emerging economies of the world, Martin says.

"The IMF's World Economic Outlook projects an emerging markets forecast with growth at 5.6% in 2013. That's down slightly from 2011 but far ahead of the measly 1.5% growth projected in the 'advanced economies'," Martin said. "That means investors need to focus heavily their investments in emerging markets, as we have done successfully over the past few years."

Besides, there's just no getting around the basic fact that emerging-economy stocks are flat out cheap right now. The broader emerging markets universe was recently trading at a 20% discount to the developed world. And with that valuation discount comes the potential for growth – and profits.

There's another piece to this strategic puzzle, too, Martin says. The big run-up we've seen in U.S. stocks has largely been fueled by the "zero-interest-rate policy" (ZIRP) of the U.S. Federal Reserve – and not by a big improvement in the health of the American business climate and U.S. economy. So any tightening of that easy-money policy could be disastrous for stocks.

And with the political skirmishes clearly on the upswing, there's also a very good chance that increasing uncertainty or some political "shock" could take a sledgehammer to stock prices here in the U.S. market.

Given those possibilities, Martin also sees the shift toward emerging-markets investments as a safety move.  But you still have to be very selective to profit.

"My principal advice for 2013 is to stay away from places where there's likely to be trouble, such as the United States and Europe. So my pick is DBS Group Holdings Ltd (PINK ADR: DBSDY), the largest bank in Singapore. It has a focus on wealth-management, which is a growth business in that center of finance. And it's a business that's much less dangerous than investment banking. Since its strength is in that region, it should benefit from its growth and avoid the problems of the wicked West.

Recommendation: Buy DBS Group Holdings Ltd (OTC: DBSDY), recent price: $47.70.

R. Shah Gilani, Editor of the Capital Wave Forecast

We're referring to it as "Crash Insurance," and it may be the savviest pick in this entire report.

Given that it came from Shah – a retired hedge fund manager and one of the savviest chroniclers of Wall Street's misdeeds that you'll find – that's not a surprise.

Although Shah has developed into an exceptional columnist in his post-Wall Street post, he hasn't lost his ability to make gutsy predictions, or to find unique ways for his readers to make money. One of his mantras – which I count among my favorites, in fact – is that "successful investors understand that it's possible to make money in every single kind of market … there's always a way."

That brings us to his recommendation for this year's guru report – the "Crash Insurance" I referred to above.

This recommendation is actually the iPath S&P 500 VIX Futures ETN (NYSEArca: VXX), which tracks the Chicago Board Options Exchange Market Volatility Index, also known as "The VIX." Often referred to as the "fear gauge" or the "fear index," the VIX represents one measure of expected volatility in the stock market in the 30 days to come.

In other words, "The VIX" often soars in value when investors get scared – as they do when markets decline. And that means the VXX ETN zooms, as well.

Two times already this year, we've seen this recommendation function just as Shah said it would.

Back on Monday Feb. 25, "The VIX" soared 34% as worries about political instability in Europe caused U.S. stocks to plummet.

That was the biggest one-day surge in the "Fear Gauge" since August 2011. And it caused the VXX ETN – our "Crash Insurance" pick – to rocket 13.7% in that single trading session.

A gain like that more than offset the 2% decline in the Standard & Poor's 500 Index.

Just so you know this wasn't a fluke, we can show you another instance where our "Crash Insurance" play paid off just as Shah intended.

April 15 was another ugly Monday for the U.S. financial markets. Gold prices plunged more than 9% and the S&P 500 took a 2.3% hit – its worst haircut in six months.

But Shah's VXX ETN recommendation soared 11.83% – which is just how insurance is supposed to work.

And that's exactly why Shah likes it, and refers to it as a "one-part hedge/one-part profit play" opportunity for Private Briefing subscribers.

"When you think about it, Bill, no one's outlawed greed, nor has anyone outlawed fear," Shah told me. "It doesn't matter if you see those two realities as having an inverse relationship, or believe that they are somehow joined in their DNA … what matters is that there's an index and a tradable instrument that enables us to hedge ourselves – or even to bet on fear and greed rearing their heads … in unison, and usually at the absolute worst possible time for our other investments."

As Shah explained it to me, now is an excellent time to take out a fear-and-greed protection policy – just by taking a position in the VXX.

"Just look at a chart of the VXX: It looks like it's fallen off a cliff – in fact, it's fallen and can't get up," Shah continued. "If this was a stock that we were looking at, you wouldn't touch it because it looks like the company is going out of business. But as we consistently remind our subscribers, fear and greed never go out of business. It's the world's only full-time concession."

As Shah explains, the VIX has been massively subdued for the following key reasons:

  1. The U.S. Federal Reserve is feeding the bull market.
  2. The bulls aren't afraid of anything with the backing of the Fed.
  3. There's nowhere else to put your money that makes sense, but in stocks.
  4. We haven't had a correction – or even any serious market fear – for a long time, and the VIX reflects that.
  5. When there's little fear of a sell-off, there's no reason to buy "Puts," which increases their premium prices and the VIX.
  6. When the market is sideways, or trending slowly higher, selling "Puts" and "Calls" for income is a basic strategy and selling options, which drives down premiums, depresses the VIX.

Now that we understand why the VIX has been "massively subdued," the next step is to fully understand why it can't stay this low forever. It can't because:

  1. This "rising-tide" market has yet to experience a meaningful correction of any type, and the traders and investors who keep tiptoeing in as we go higher will be the first to race back to their fixed-income security blanket if we get a sell-off. And this reality could trigger stops that are below new support levels. If that happens – and there are exacerbating events – the resultant "cascading effect" could easily tank the markets.
  2. None of the world's macro headwinds – such as the Eurozone debt crisis and the fiscal quagmire in Washington, just to name two – have been resolved. And because they continue to linger, they can also erupt anew at any time.
  3. The anemic trading volume is indicative of a tepid investing environment. No one knows if there is any depth under the bull market.
  4. Fear is alive and well – it's just become "comfortably numb."

"Bill, tell your subscribers to buy the VXX and put it away for a rainy day," Shah said. "Now is the perfect time. It's a cheap insurance policy whose price is only the opportunity cost of using that small amount of capital to buy something else. It's worth it, especially at these levels."

Recommendation: Buy some "Crash Insurance" – the iPath S&P 500 VIX Futures ETN (NYSEArca: VXX).

There you have it – seven recommendations for this year. We'll keep you updated. And feel free to drop us a line now and then. Just write to us at